The 10 analysts offering 12-month price forecasts for Arrowhead Pharmaceuticals Inc have a median target of 77.00, with a high estimate of 110.00 and a low estimate of 39.00. The median estimate represents a +59.32% increase from the last price of 48.33.
The current consensus among 10 polled investment analysts is to Buy stock in Arrowhead Pharmaceuticals Inc. This rating has held steady since July, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.39
Reporting Date Dec 13
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.